Complete Response to Enfortumab Vedotin in a Hemodialysis Patient with Metastatic Urothelial Carcinoma: A Case Report

Complete Response to Enfortumab Vedotin in a Hemodialysis Patient with Metastatic Urothelial Carcinoma: A Case Report

Enfortumab vedotin (EV) is an antibody-drug conjugate and a promising agent for metastatic urothelial carcinoma (mUC). However, evaluations in end-stage renal disease patients undergoing hemodialysis are unreported. Here, we report such a case. A 74-year-old woman with mUC, on hemodialysis for compl...

Full description

Bibliographic Details
Main Authors: Bunpei Isoda, Masanobu Shiga, Shuya Kandori, Yoshiyuki Nagumo, Takayuki Yoshino, Atsushi Ikeda, Takashi Kawahara, Tomokazu Kimura, Hiromitsu Negoro, Akio Hoshi, Bryan J Mathis, Hiroyuki Nishiyama
Format: Article
Language:English
Published: Karger Publishers 2023-06-01
Series:Case Reports in Oncology
Subjects:
enfortumab vedotin
hemodialysis
metastatic urothelial carcinoma
Online Access:https://beta.karger.com/Article/FullText/530780

Internet

https://beta.karger.com/Article/FullText/530780

Similar Items